HK Stock MarketDetailed Quotes

01477 OCUMENSION-B

Watchlist
  • 5.780
  • +0.050+0.87%
Market Closed Mar 28 16:08 CST
4.02BMarket Cap-9601P/E (TTM)

About OCUMENSION-B Company

We are a Chinese ophthalmology platform company dedicated to identifying, developing and commercializing first-of-its-kind or best-in-class ophthalmic treatments. Our vision is to provide world-class overall pharmaceutical solutions to meet the huge demand gap in ophthalmology care in China. We believe that our ophthalmology platform, which has a clear first-mover advantage, will enable us to take a leading position in the Chinese ophthalmology industry. With our platform, we have built a comprehensive, innovative and proven ophthalmic drug portfolio carefully designed at a strategic level. As of the date of this report, we have 18 drug assets covering all major anterior and posterior eye conditions. We have five major drug candidates in the phase III clinical trial development stage in China. We believe that if approved, these candidates may be the first of their kind or the best in their class, and will show significant short-term earnings potential as early as 2022. Our product portfolio includes three of the ten ophthalmic drugs approved by the FDA since 2015 but not marketed in China using any process. Additionally, our product portfolio includes three drugs that are in or near commercialization. The table below provides an overview of our product portfolio and individual drug asset status as of the date of this report.

Company Profile

Symbol01477
Company NameOCUMENSION-B
ISINKYG674111011
Listing Date07/10/2020
Issue Price14.66
Shares Offered105.93M share
Founded02/27/2018
RegistrationCayman Islands
ChairmanLian Yong CHEN
SecretaryTingchan\ruantianshi Chen
Audit InstitutionDeloitte & Touche Tohmatsu Certified Public Accountants
Company CategoryOverseas registration of Mainland Individuals control
Registered OfficeVistra (Cayman) Limited Office P.O. Box 31119 Grand Pavilion Hibiscus Way 802 West Bay Road Grand Cayman KY1-1205 Cayman Islands
Head Office and Principal Place of BusinessRoom 417, 4th floor, Tower 2, Lippo Centre, 89 Queensway, Admiralty, Hong Kong
Fiscal Year Ends12-31
Employees444
MarketHong Kong motherboard
Phone(86)02122893600;(1)6173741610
Emailinfo@ocumension.com
Business Okanvision Biotech is a Chinese holding company that is mainly engaged in the discovery, development and commercialization of ophthalmic therapies. Its main products include OT-401 (YUTIQ), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-301 (NCX 470), OT-101, and OT-202. The company operates within China.

Company Executives

  • Name
  • Position
  • Salary
  • Ye LIU
  • CEO,Executive Director,Authorized Representative
  • --
  • Zhaopeng Hu
  • Executive Director,Chief Development Officer
  • --
  • Lian Yong CHEN
  • Chairman of the Board,Non-Executive Director,Nomination Committee Chairman
  • --
  • Wei LI
  • Non-Executive Director
  • --
  • Yanling Cao
  • Non-Executive Director
  • --
  • Yumeng Wang
  • Non-Executive Director
  • --
  • Dingxu Hu
  • Independent Non-Executive Director,Audit Committee Chairman,Remuneration Committee Member
  • --
  • Yiran Huang
  • Audit Committee Member,Remuneration Committee Member,Independent Non-Executive Director,Nomination Committee Member
  • --
  • Donghong(donghong chen) Chen
  • Chief Medical Officer
  • --
  • Qinglei Zuo
  • Chief Commercial Officer
  • --
  • Tianshi Ruan
  • Joint Company Secretary,Authorized Representative,CFO
  • --
  • Tingchan Chen
  • Joint Company Secretary
  • --
  • Zhenyu Zhang
  • Nomination Committee Member,Independent Non-Executive Director,Audit Committee Member,Remuneration Committee Chairman
  • --

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
HK
Overall
Symbol
Latest Price
%Chg